BioPivot Review: What Its GLP-1 Documents Establish—and What They Do Not

BioPivot’s public documentation answers some concrete questions: which compounded medicines it markets, what several plans cost, and which organizations it names for clinical care and pharmacy fulfillment. It does not establish that its particular preparations or microdosing programs produce the outcomes associated with major clinical trials. That distinction is the starting point for this review: evidence that a service is offered is different from evidence that its treatment achieves a particular result.

The pages consulted October 19, 2026, describe a U.S. telehealth platform with online intake, independent prescribing, pharmacy fulfillment, messaging and recurring payments. They also contain meaningful inconsistencies, especially a promise of no charge if treatment is declined alongside a policy retaining $59. For adults considering BioPivot, the useful task is to separate documented offerings, provider claims, independent clinical context and unresolved questions before entering payment information.

At a glance

Business model: BioPivot, LLC describes itself as a technology platform, not the organization practicing medicine or preparing or dispensing medication.
Sources: [10]
Named service partners: The site identifies Elite Care Health for clinical care and Rx Ave Health for pharmacy and prescription fulfillment.
Sources: [12]
Published treatment prices: Compounded semaglutide Starter is listed at $185 monthly or $400 quarterly; compounded tirzepatide Starter is $242 monthly or $590 quarterly.
Sources: [11] [6]
Conflicting consultation charges: The homepage advertises $0 if an applicant is not approved, but the refund policy retains a $59 doctor consultation fee after clinical rejection.
Sources: [12] [9]
Evidence boundary: BioPivot acknowledges that compounded medications are not FDA approved. Clinical trials do not establish outcomes for its particular preparations or microdosing plans.
Sources: [12] [1] [3] [4]

Start with the product, not the ingredient’s reputation

BioPivot markets compounded semaglutide and compounded tirzepatide in Starter, Continuation and Maintenance plans, plus separate options labeled microdosing. These are documented commercial categories, not proof of distinct clinical benefits. The consulted text does not expressly establish the administration route, exact presentation or supplied quantity for the GLP-1 products. An ingredient name and a plan label therefore leave important product-level questions unanswered.

The platform acknowledges that compounded medicines are not FDA approved. FDA explains that these preparations do not undergo its premarket review for safety, effectiveness and quality, and recommends them when an individual’s medical needs cannot be met by an approved drug. Nonapproval alone does not demonstrate clinical inequivalence. It also does not justify borrowing an approved product’s evidence without qualification. Our guide to approved medicines and compounded preparations explains that distinction.

BioPivot’s policy says all medications dispensed through its service are custom-made preparations from licensed 503A compounding pharmacies. That is the company’s representation, not an independently verified finding here. The public material does not identify which specific preparing pharmacy would handle an individual prescription. Before purchase, the useful evidence request is the actual product description and dispensing pharmacy—not simply reassurance that a familiar ingredient appears in the plan name.

Sources: [11] [6] [8] [12] [9] [1]

What research can—and cannot—say about these plans

STEP 1 studied subcutaneous semaglutide in adults without diabetes, while SURMOUNT-1 studied subcutaneous tirzepatide in adults without diabetes. Neither was a trial of BioPivot, its pharmacy partners or its compounded preparations. Their findings cannot establish this platform’s effectiveness, predict an individual result or validate a different route or microdosing approach. A clinical trial is not a company performance report, even when both discussions use the same ingredient name.

The consulted documentation does not establish provider-specific treatment outcomes. In particular, descriptions suggesting greater potency, faster results or fewer adverse effects from microdosing should remain attributed marketing claims rather than review conclusions. A lower advertised price or a smaller-sounding treatment label is not evidence of a better benefit–risk balance. The material does not supply a basis for ranking BioPivot’s microdosing options against its other programs or against approved products.

NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines, family history and costs. Follow-up should address response and tolerance, not just payment renewal. Those principles help identify what an individualized consultation should cover, but they do not verify BioPivot’s delivery of that care. The platform’s documented messaging and check-ins are service promises; their clinical quality cannot be determined from the public descriptions alone.

Sources: [3] [4] [2] [8] [11]

Who is responsible for the care

BioPivot, LLC owns and operates the website, but its terms say it acts solely as a technology platform. It says it does not practice medicine, provide clinical care, prepare or dispense medication, or control independent professional judgment. This division matters when interpreting a single bundled purchase: the platform, clinical organization and pharmacy may have different responsibilities even when the customer encounters them through one website and one payment.

The homepage identifies Elite Care Health for clinical care, listing mayur@elite-care.health and 810-348-3003. For pharmacy and prescription fulfillment, it names Rx Ave Health, with info@rxave.health and (833) 360-4276. These are useful contact paths, but naming a fulfillment organization does not establish which pharmacy compounds a particular prescription. The site’s claims about U.S. board-certified clinical providers and state-licensed pharmacies were not independently verified for this review.

The terms also restrict pharmacy choice: purchasing a prescription-containing service requires accepting fulfillment through the platform’s pharmacies and waiving the ability to choose another pharmacy under that arrangement. Anyone wanting an outside pharmacy should resolve that issue before paying. More generally, ask which organization handles clinical questions, prescription changes, dispensing concerns and billing disputes. The public documents identify several participants, but do not make every handoff equally clear.

Sources: [10] [12]

Published prices are specific; the billing structure is less settled

BioPivot provides considerably more pricing detail than its homepage’s unexplained “from $149” monthly offer. That minimum is subject to provider review, but the consulted material does not identify its product or conditions. Treatment pages advertise 20% off the first order with BIOPIVOT20, with prescribing conditional on clinical appropriateness. The table reports listed prices without applying that promotion; it should not be read as a statement of supply quantity or a required quarterly prepayment.

BioPivot’s listed compounded treatment prices; GLP-1 route and presentation are not expressly established in the consulted text.
Compounded plan	Monthly option	Quarterly option
Semaglutide Starter	$185	$400
Semaglutide Continuation / Maintenance	$218 / $225	$490 / $518
Tirzepatide Starter	$242	$590
Tirzepatide Continuation / Maintenance	$315 / $350	$780 / $900
Microdosing: semaglutide / tirzepatide	$168 / $220	$370 / $528

Sources: [11] [6] [8] [12] [9] [10]

What the package includes—and what intake actually promises

The terms describe a bundled price covering the pharmacy’s prescription charge, medical-group services and platform access. Separately, the cancellation policy describes a three-month membership, while recurring-order terms authorize an immediate charge and further charges every 30 days, with electronic notice five to seven days beforehand. These statements do not fully explain how monthly and quarterly options interact. Nor do they establish quarterly prepayment conditions or a universal minimum commitment. Obtain the applicable checkout schedule in writing.

The flat-rate program advertises compounded medication, structured shipping, direct physician messaging through a secure portal and scheduled check-ins. Exact review and shipment frequencies are not stated. The homepage also advertises clinically appropriate baseline and monitoring labs, and lists a Comprehensive Panel at $228.30 without establishing whether that charge is included in a program. Insurance acceptance, HSA/FSA use and possible separate charges for supplies or additional services are not documented clearly enough to assume coverage.

Intake begins with a brief online form reviewed before a conversation with a physician. A licensed medical provider may request more information, labs or a consultation before deciding whether to prescribe. Selecting a plan does not guarantee treatment. The site says most applicants hear back within 48 hours, which is a review-response claim—not a prescription, dispatch or arrival promise. Its BMI calculator is described as preliminary, with eligibility determined during assessment.

Sources: [10] [9] [11] [12]

Eligibility and continuing access have practical boundaries

The terms require users to be at least 18, or the age of majority where they live if higher. During a provider consultation, patients must physically be in the same state as the shipping address on their account. BioPivot says telehealth may be available in all 50 states where clinically appropriate and legally permitted. That conditional statement is not confirmation that every product is available to every applicant in every state.

Treatment pages state that the products are not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN 2, or for those who are pregnant or breastfeeding. They also say a full medical history is reviewed before prescribing. These are the provider’s stated restrictions, not a complete individualized eligibility assessment. The public text does not establish that satisfying these conditions guarantees acceptance or that a BMI estimate settles the decision.

For general support, BioPivot publishes info@biopivot.co and 520-210-4673. Its contact page lists clinical hours as Monday through Friday, 9 a.m. to 5 p.m., without specifying a time zone in that block. The contact form promises a response within 24 hours, a different claim from intake review timing. After-hours clinical access, Spanish-language care and interpreter availability remain unconfirmed. Readers can use our follow-up guide to prepare questions about ongoing care rather than assuming messaging means continuous coverage.

Sources: [10] [12] [11] [7] [2]

Cancellation reveals the most important documentary conflicts

The homepage says the first review is free and advertises “$0 if you’re not approved.” The cancellation policy says something materially different: when a provider reviews intake and declines treatment, the membership payment is refunded minus a $59 doctor consultation fee. Before clinical evaluation begins, the policy permits a full refund of paid membership or intake fees. These are different financial outcomes. The public material does not resolve which promise controls an applicant’s transaction.

Cancellation can be requested through Account > Subscription > Cancel Membership, by email with the account holder’s name and email address, or by phone. The policy says requests are processed within one business day and benefits remain through the three-month membership period. However, subscription terms require switching off auto-refill at least 48 hours before the monthly processing date. An ability to request cancellation at any time does not erase that stated renewal deadline or establish a refund.

After prescribing but before shipment, the policy describes a partial refund less $59, yet warns cancellation cannot be guaranteed once the order reaches the pharmacy. After shipment, compounded-medication sales are final except for specified pharmacy errors or damaged or incorrect deliveries. Approved refunds are processed in five to ten business days; banks may need another three to five business days to display the credit. Processing a refund is not the same as receiving it.

Sources: [12] [9] [10]

Delivery and privacy deserve their own evidence checks

BioPivot advertises discreet, temperature-controlled delivery in unmarked packaging, but does not document preparation, dispatch or arrival timelines in the consulted text. Damaged or incorrect orders must be reported with photographs within seven days of delivery for a no-cost replacement. Tracking-confirmed losses must be reported within 14 days of expected delivery for reshipment without an additional charge. The terms also warn that prescription products will not be dispensed in child-resistant containers.

Temperature-controlled packaging is a shipping claim, not proof that a particular delivery stayed within appropriate conditions. For an injectable GLP-1 drug arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. BioPivot’s GLP-1 route is not expressly documented here, so that guidance is conditional rather than a description of every shipment. Our delivery-evidence guide explains why packaging and verified arrival condition are separate questions.

There are also unresolved privacy-document details. The terms name Pura Labs LLC in a HIPAA passage without explaining its relationship to BioPivot. The general privacy statement says BioPivot does not sell, rent or trade personal information, while the California notice describes advertising disclosures that may count as a sale or sharing under that law and states its priority for California consumers. These differences warrant clarification; they do not establish a legal violation or reveal an undisclosed corporate relationship.

Sources: [11] [10] [9] [5] [1]

Questions & answers

What would I pay if BioPivot declines treatment?

The public documents conflict. The homepage advertises $0 if you are not approved, while the refund policy retains $59 after a provider reviews intake and decides you are not a candidate. Before clinical evaluation begins, the policy allows a full refund of membership or intake fees paid. Ask for written confirmation of the rule applicable to your purchase before submitting payment.

Sources: [12] [9]

Is BioPivot’s $149 monthly offer the semaglutide Starter plan?

That connection is not established. The homepage advertises plans from $149 monthly, confirmed after provider review, without identifying the qualifying product or conditions. The separate compounded semaglutide Starter listing is $185 monthly or $400 quarterly. The treatment pages also advertise a first-order promotion, but that does not explain the homepage minimum or establish a continuing discounted price.

Sources: [12] [11]

Does choosing quarterly pricing establish a three-month medication supply?

No supplied quantity is established by that price label. BioPivot lists quarterly options, describes a three-month membership elsewhere, and has terms for recurring charges every 30 days. Those statements do not fully reconcile billing, supply and commitment. Ask for the amount collected initially, subsequent charge dates, shipment quantities and cancellation consequences for the specific option you select.

Sources: [11] [9] [10]

Are BioPivot’s microdosing plans proven to cause fewer side effects?

The consulted evidence does not establish that claim. BioPivot lists compounded semaglutide microdosing at $168 monthly or $370 quarterly and compounded tirzepatide microdosing at $220 monthly or $528 quarterly. Those prices document an offering, not comparative tolerability. STEP 1 and SURMOUNT-1 do not validate these particular microdosing preparations, and their results should not be presented as BioPivot outcomes.

Sources: [8] [3] [4]

Can I take a BioPivot prescription to my preferred pharmacy?

The terms make prescription-containing purchases conditional on accepting the platform’s pharmacy arrangement and waiving pharmacy choice for that purchase. They say not to buy the service if you do not want to accept that condition. Rx Ave Health is named for pharmacy fulfillment, but the consulted documentation does not identify the specific preparing pharmacy for each patient.

Sources: [10] [12]

What should I clarify about labs before enrolling?

Ask whether your evaluation requires labs, where collection occurs and which charges are separate. BioPivot advertises clinically appropriate baseline and monitoring testing and lists a Comprehensive Panel at $228.30, but does not establish whether that price is included in a program. Its Tasso home capillary-collection kit is labeled coming soon, with no price; that is not confirmation of currently available home testing.

Sources: [12]

Our assessment

BioPivot documents a recognizable service model: named clinical and fulfillment organizations, multiple compounded-treatment prices, online assessment, messaging and delivery policies. Those details support an account of what it markets, not a finding that its preparations or microdosing plans reproduce clinical-trial outcomes. The most consequential unresolved issues are the $0-versus-$59 rejection charge, the relationship between monthly billing and three-month membership language, and the precise product and pharmacy assigned to a patient. A useful next step is written clarification of those points, including route, presentation, supply, lab charges and renewal deadlines. The documentation is informative enough to generate specific questions, but not to support a safety endorsement, efficacy ranking or confident estimate of every applicant’s total obligation.

Visit BioPivot’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

BioPivot Review: What Its GLP-1 Documents Establish—and What They Do Not

At a glance

01Start with the product, not the ingredient’s reputation

02What research can—and cannot—say about these plans

03Who is responsible for the care

04Published prices are specific; the billing structure is less settled

05What the package includes—and what intake actually promises

06Eligibility and continuing access have practical boundaries

07Cancellation reveals the most important documentary conflicts

08Delivery and privacy deserve their own evidence checks